20 March 2020
Visiongain has launched a new pharma report: Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Disease.
This report encompasses the global market for pharmaceutical clinical trial services. It provides a comprehensive and critical analysis of the market, including the subsectors of early phase services and late phase services. The report also assesses the key therapeutic areas in which leading clinical research organizations (CROs) operate, namely, cancer, cardiovascular disease, CNS disease, infectious diseases and metabolic disease.
The lead analyst of the report commented "Biotech, pharmaceutical & medical device companies continue to develop at a fast pace owing to continuous expenditure on R&D, rising demand for biopharmaceuticals and increased healthcare needs for the geriatric population. In order to fulfil this, the demand for effective clinical trials has increased in order to ensure the effectiveness and safety of products. This demand is further propelled by the increasing importance of contract research organizations in emerging markets. The main challenges faced in this market are the lengthy authorisation, and approval procedures imposed by regulatory authorities."
Leading companies featured in the report include Quintiles, Laboratory Corporation of America (LabCorp), Pharmaceutical Product Development (PPD), Parexel International, ICON, INC Research Holdings, inVentiv Health & Other Companies
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.